Dyne Therapeutics, Inc.

The current price of DYN is $17.36 — it has decreased by 6.36% since the previous close. Data as of Nov 5, 2026.

DYN is up 2.30% over the past week, up 12.44% over the past month and down 16.94% over the past year. The price is below its 200-day moving average of $19.33.

Analysts' average 12-month price target for DYN is $35.20, which implies 102.76% upside from the current price. Individual estimates range from $24.00 to $50.00.

Of the 17 analysts covering Dyne Therapeutics, Inc., 3 rate it a strong buy, 12 rate it a buy, 1 rates it a hold and 1 rates it a strong sell. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

Dyne Therapeutics, Inc. has a market capitalization of $3.24B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

In its most recent quarterly report, Dyne Therapeutics, Inc. posted a loss of $1.06 per share against an estimate of -$0.9073, missing expectations by 16.83%. Upcoming reports are listed in the earnings calendar.

Dyne Therapeutics, Inc. has not paid any dividends over the past year.

Companies most comparable to Dyne Therapeutics, Inc. include Ionis Pharmaceuticals, Inc., PTC Therapeutics, Inc., Sarepta Therapeutics, Inc., Stoke Therapeutics, Inc. and Solid Biosciences Inc.

In the latest trading session DYN moved between $17.33 and $18.78, a range of 8.35% of its current price.

Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Dyne Therapeutics, Inc. shows a neutral rating today and a sell rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Dyne Therapeutics, Inc. is sell. Technical ratings are indicators, not investment advice.

Over the past 52 weeks DYN has traded between $14.00 and $27.31. The current price is 36.43% below its 52-week high.